294
Participants
Start Date
June 27, 2011
Primary Completion Date
July 31, 2013
Study Completion Date
March 17, 2014
vaniprevir
Capsules containing 150 mg vaniprevir, orally, two in the morning and two in the evening for 12 or 24 weeks
Placebo to vaniprevir
Placebo to vaniprevir, capsules, orally, twice daily for 12 weeks or 24 weeks
Peg-IFN
Peg-IFN 1.5 μg/kg once per week, subcutaneously (SC) for 24 or 48 weeks
ribavirin
Capsules containing 200 mg RBV orally, 3 to 5 capsules, dosage based on the participant's weight (600 mg/day to 1000 mg/day), for 24 or 48 weeks
Merck Sharp & Dohme LLC
INDUSTRY